226 related articles for article (PubMed ID: 16762150)
1. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.
Kullich WC; Mur E; Aglas F; Niksic F; Czerwenka C
Clin Exp Rheumatol; 2006; 24(2):155-60. PubMed ID: 16762150
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
Skoumal M; Kolarz G; Klingler A
Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
[TBL] [Abstract][Full Text] [Related]
3. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
[TBL] [Abstract][Full Text] [Related]
4. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
Morozzi G; Fabbroni M; Bellisai F; Cucini S; Simpatico A; Galeazzi M
Clin Rheumatol; 2007 Aug; 26(8):1335-8. PubMed ID: 17285224
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-1alpha-induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid.
Ganu V; Goldberg R; Peppard J; Rediske J; Melton R; Hu SI; Wang W; Duvander C; Heinegård D
Arthritis Rheum; 1998 Dec; 41(12):2143-51. PubMed ID: 9870871
[TBL] [Abstract][Full Text] [Related]
7. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation.
Neidhart M; Hauser N; Paulsson M; DiCesare PE; Michel BA; Häuselmann HJ
Br J Rheumatol; 1997 Nov; 36(11):1151-60. PubMed ID: 9402858
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
[TBL] [Abstract][Full Text] [Related]
9. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients.
Targońska-Stępniak B; Dryglewska M; Majdan M
Pharmacol Rep; 2010; 62(4):719-25. PubMed ID: 20885012
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
12. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
Wisłowska M; Jabłońska B
Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
[TBL] [Abstract][Full Text] [Related]
13. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
[TBL] [Abstract][Full Text] [Related]
14. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
de Jong Z; Munneke M; Vilim V; Zwinderman AH; Kroon HM; Ronday HK; Lems WF; Dijkmans BA; Breedveld FC; Vliet Vlieland TP; Hazes JM; Degroot J
Rheumatology (Oxford); 2008 Jun; 47(6):868-71. PubMed ID: 18400837
[TBL] [Abstract][Full Text] [Related]
15. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs.
Dickinson SC; Vankemmelbeke MN; Buttle DJ; Rosenberg K; Heinegård D; Hollander AP
Matrix Biol; 2003 May; 22(3):267-78. PubMed ID: 12853037
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP).
Stracke JO; Fosang AJ; Last K; Mercuri FA; Pendás AM; Llano E; Perris R; Di Cesare PE; Murphy G; Knäuper V
FEBS Lett; 2000 Jul; 478(1-2):52-6. PubMed ID: 10922468
[TBL] [Abstract][Full Text] [Related]
17. Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model.
Chu XQ; Wang JJ; Dou LD; Zhao G
Genet Mol Res; 2015 Nov; 14(4):14207-15. PubMed ID: 26600478
[TBL] [Abstract][Full Text] [Related]
18. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis.
Gomez-Barrena E; Lindroos L; Ceponis A; López-Franco M; Sanchez-Pernaute O; Mönkkönen J; Salo J; Herrero-Beaumont G; Konttinen Y
Clin Exp Rheumatol; 2006; 24(6):622-8. PubMed ID: 17207376
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
Tchetverikov I; Kraan MC; van El B; Hanemaaijer R; DeGroot J; Huizinga TW
Ann Rheum Dis; 2008 Jan; 67(1):128-30. PubMed ID: 17875551
[TBL] [Abstract][Full Text] [Related]
20. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
